Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer

Gastric Cancer is one of the leading causes of cancer-related death worldwide, and patients with unresectable locally advanced or metastatic disease have a poor prognosis. This study aims to evaluate the safety and efficacy of radiotherapy combined with CAPOX and SHR-1701, a PD-L1/TGF-β bispecific antibody, in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. By improving local tumor control and enhancing systemic antitumor activity, this study seeks to increase the opportunity for curative-intent resection and improve survival outco

Trial Details

NCT ID
NCT07689851
Phase
PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • COPOX
  • Radiotherapy
  • SHR-1701
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Taiyuan, Shanxi, China|37.86944,112.56028
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Male or female participants aged 18 to 75 years.
  • Histologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
  • Unresectable locally advanced or metastatic gastric cancer, with primary and metastatic lesions amenable to radiotherapy (excluding patients with b…
  • HER2-negative disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →